Ten firms led a market rally with whopping gains on Thursday, outperforming the lackluster performance of the major indices ...

Discover the top stock picks by market experts Raja Venkatraman, MarketSmith India, Ankush Bajaj and Trade Brains for ...

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

Adults with atopic dermatitis treated with upadacitinib had fewer major adverse cardiovascular events compared with ...

Additional safety signals have been identified with apremilast, with some adverse events specific to certain patient populations.

John Mauceri, an award-winning music conductor, author, and recording artist, is celebrating his return to the stage in ...

This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in ...

The action expands upon the company’s October 2024 revenue forecast of around $1 billion in sales during the first year, with ...

John Mauceri had a complicated health history, but his sudden swelling and fatigue left his team of doctors stumped.

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

Metabolic syndrome is associated with elevated levels of pain catastrophizing among patients with PsA and may impact disease activity.